Does the CCR5-Δ32 mutation explain the variable coronavirus-2019 pandemic statistics in Europe?
作者信息
Starčević Čizmarević Nad, Tota Marin, Ristić Smiljana
机构信息
Nada Starčević Čizmarević, Department of Medical Biology and Genetics, Faculty of Medicine, University of Rijeka, Rijeka, Croatia,
出版信息
Croat Med J. 2020 Dec 31;61(6):525-526. doi: 10.3325/cmj.2020.61.525.
Abstract
摘要
相似文献
1
Does the CCR5-Δ32 mutation explain the variable coronavirus-2019 pandemic statistics in Europe?CCR5-Δ32突变能否解释欧洲2019冠状病毒病大流行统计数据的差异？
Croat Med J. 2020 Dec 31;61(6):525-526. doi: 10.3325/cmj.2020.61.525.
2
Could the CCR5-Delta32 mutation be protective in SARS-CoV-2 infection?CCR5-Delta32 突变是否可能对 SARS-CoV-2 感染具有保护作用？
Physiol Res. 2021 Dec 16;70(S2):S249-S252. doi: 10.33549/physiolres.934725.
3
CCR5 Δ32 minorallele is associated with susceptibility to SARS-CoV-2 infection and death: An epidemiological investigation.CCR5 Δ32 次要等位基因与感染 SARS-CoV-2 及死亡的易感性相关：一项流行病学调查。
Clin Chim Acta. 2020 Nov;510:60-61. doi: 10.1016/j.cca.2020.07.012. Epub 2020 Jul 10.
4
Impact of Genetic Variability in ACE2 Expression on the Evolutionary Dynamics of SARS-CoV-2 Spike D614G Mutation.ACE2 表达中的遗传变异性对 SARS-CoV-2 刺突 D614G 突变进化动态的影响。
Genes (Basel). 2020 Dec 24;12(1):16. doi: 10.3390/genes12010016.
5
Acute Kidney Injury in COVID-19 Pandemic.新冠疫情中的急性肾损伤
Nephron. 2020;144(7):345-346. doi: 10.1159/000508381. Epub 2020 May 19.
6
Updated rapid risk assessment from ECDC on coronavirus disease (COVID-19) pandemic in the EU/EEA and the UK: resurgence of cases.欧洲疾病预防控制中心（ECDC）关于欧盟/欧洲经济区及英国冠状病毒病（COVID-19）大流行的最新快速风险评估：病例再度出现。
Euro Surveill. 2020 Aug;25(32). doi: 10.2807/1560-7917.ES.2020.25.32.2008131.
7
Could DIZE be the answer to COVID-19?二氢杨梅素（DIZE）会是新冠病毒病（COVID-19）的解决方案吗？
Maturitas. 2020 Oct;140:83-84. doi: 10.1016/j.maturitas.2020.07.002. Epub 2020 Jul 2.
8
[In Focus: SARS-CoV-2 and the COVID-19 Pandemic].[聚焦：严重急性呼吸综合征冠状病毒2（SARS-CoV-2）与冠状病毒病（COVID-19）大流行]
Handchir Mikrochir Plast Chir. 2020 Jun;52(3):220. doi: 10.1055/a-1173-5888. Epub 2020 Jun 12.
9
EU health law and policy in and after the COVID-19 crisis.新冠疫情危机期间及之后的欧盟卫生法律与政策。
Eur J Public Health. 2020 Aug 1;30(4):623-624. doi: 10.1093/eurpub/ckaa088.
10
Detectable Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Human Breast Milk of a Mildly Symptomatic Patient With Coronavirus Disease 2019 (COVID-19).检测到轻度症状的 2019 冠状病毒病（COVID-19）患者的人乳中存在可检测的严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）。
Clin Infect Dis. 2021 Jan 23;72(1):128-130. doi: 10.1093/cid/ciaa673.
引用本文的文献
1
Role of ACE1, ACE2, and CCR5-Δ32 Polymorphisms in the Transmission of SARS-CoV-2 to Intimate Contacts.ACE1、ACE2和CCR5-Δ32基因多态性在严重急性呼吸综合征冠状病毒2（SARS-CoV-2）向密切接触者传播中的作用
Biology (Basel). 2025 May 22;14(6):587. doi: 10.3390/biology14060587.
2
Investigating the Potential Impact of CCR5-Δ32 Variant on COVID-19 Outcome: A Case-Control Study in Iranian Population.探究CCR5-Δ32变异体对COVID-19结局的潜在影响：伊朗人群的一项病例对照研究。
Iran J Public Health. 2024 Aug;53(8):1864-1870. doi: 10.18502/ijph.v53i8.16292.
3
Allelic Variations in the Human Genes and and the Resistance to Viral Infection by SARS-CoV-2.人类基因中的等位变异与对 SARS-CoV-2 病毒感染的抵抗力。
Int J Mol Sci. 2022 Aug 15;23(16):9171. doi: 10.3390/ijms23169171.
4
Host polymorphisms and COVID-19 infection.宿主基因多态性与新型冠状病毒肺炎感染
Adv Clin Chem. 2022;107:41-77. doi: 10.1016/bs.acc.2021.07.002. Epub 2021 Aug 23.
5
Could the CCR5-Delta32 mutation be protective in SARS-CoV-2 infection?CCR5-Delta32 突变是否可能对 SARS-CoV-2 感染具有保护作用？
Physiol Res. 2021 Dec 16;70(S2):S249-S252. doi: 10.33549/physiolres.934725.
6
Differential mortality of infectious disease in Italian polities: COVID-19, past plague epidemics, and currently endemic respiratory disease.意大利政治实体中传染病的差异死亡率：COVID-19、过去的鼠疫流行以及当前流行的呼吸道疾病。
Infect Genet Evol. 2021 Nov;95:105081. doi: 10.1016/j.meegid.2021.105081. Epub 2021 Sep 11.
7
Update on human genetic susceptibility to COVID-19: susceptibility to virus and response.新型冠状病毒肺炎（COVID-19）人类遗传易感性研究进展：病毒易感性与反应
Hum Genomics. 2021 Aug 25;15(1):57. doi: 10.1186/s40246-021-00356-x.
8
Variant-genetic and transcript-expression analysis showed a role for the chemokine-receptor CCR5 in COVID-19 severity.变异基因和转录表达分析表明趋化因子受体 CCR5 在 COVID-19 严重程度中起作用。
Int Immunopharmacol. 2021 Sep;98:107825. doi: 10.1016/j.intimp.2021.107825. Epub 2021 Jun 2.
本文引用的文献
1
An evidence for correlation between the glutathione S-transferase T1 (GSTT1) polymorphism and outcome of COVID-19.谷胱甘肽S-转移酶T1（GSTT1）基因多态性与2019冠状病毒病（COVID-19）预后之间相关性的证据。
Clin Chim Acta. 2020 Sep;508:213-216. doi: 10.1016/j.cca.2020.05.041. Epub 2020 May 23.
2
No significant correlation between ACE Ins/Del genetic polymorphism and COVID-19 infection.血管紧张素转换酶（ACE）插入/缺失（Ins/Del）基因多态性与新型冠状病毒肺炎（COVID-19）感染之间无显著相关性。
Clin Chem Lab Med. 2020 Jun 25;58(7):1127-1128. doi: 10.1515/cclm-2020-0577.
3
COVID-19 infections are also affected by human ACE1 D/I polymorphism.新型冠状病毒肺炎感染也受人类血管紧张素转换酶1 D/I多态性的影响。
Clin Chem Lab Med. 2020 Jun 25;58(7):1125-1126. doi: 10.1515/cclm-2020-0425.
4
The host's angiotensin-converting enzyme polymorphism may explain epidemiological findings in COVID-19 infections.宿主的血管紧张素转换酶多态性可能解释了新冠病毒感染中的流行病学发现。
Clin Chim Acta. 2020 Jun;505:192-193. doi: 10.1016/j.cca.2020.03.031. Epub 2020 Mar 24.
5
Frequencies of gene variant CCR5-Δ32 in 87 countries based on next-generation sequencing of 1.3 million individuals sampled from 3 national DKMS donor centers.基于对来自3个德国骨髓捐赠者登记处（DKMS）国家中心的130万人样本进行的新一代测序，87个国家的基因变体CCR5-Δ32的频率。
Hum Immunol. 2017 Nov;78(11-12):710-717. doi: 10.1016/j.humimm.2017.10.001. Epub 2017 Oct 5.
6
CCR5 deficiency predisposes to fatal outcome in influenza virus infection.CCR5基因缺陷易导致流感病毒感染出现致命后果。
J Gen Virol. 2015 Aug;96(8):2074-2078. doi: 10.1099/vir.0.000165. Epub 2015 Apr 27.
7
Frequency of CCR5 gene 32-basepair deletion in Croatian normal population.
Croat Med J. 2005 Aug;46(4):693-4.
8
Contrasting effects of CCR5 and CCR2 deficiency in the pulmonary inflammatory response to influenza A virus.CCR5和CCR2缺陷在甲型流感病毒肺部炎症反应中的对比作用。
Am J Pathol. 2000 Jun;156(6):1951-9. doi: 10.1016/S0002-9440(10)65068-7.
Zotero 插件